• Home
  • Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.

Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.

Author List
Klein-Brill A, Amar-Farkash S, Lawrence G, Collisson EA, Aran D
Publication
JAMA network open
Publication ID (Profile URL)
https://researcherprofiles.org/profile/302853297
Publication Year
2022
PubMed ID
35675073
Publication Title
Klein-Brill A, Amar-Farkash S, Lawrence G, Collisson EA, Aran D. Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. JAMA Netw Open. 2022 06 01; 5(6):e2216199.